tbuckley/cabot-search huggingface dataset:
Clinical factors associated with acute exacerbations of chronic rhinosinusitis
Authors: Jason H. Kwah, Shaan N. Somani, Whitney W. Stevens, Robert C. Kern, Stephanie S. Smith, Kevin C. Welch, David B. Conley, Bruce K. Tan, Leslie C. Grammer, Amy Yang, Robert P. Schleimer, Anju T. Peters
Journal: Journal of Allergy and Clinical Immunology (2020)
Tolerance of baked-milk in milk-triggered children with eosinophilic esophagitis (EoE)
Authors: Megan Patterson, Sarah Beckwith, Mallik Rettiganti, Chunqiao Luo, Peggy Chandler, Rebecca Levy, Helen Casteel, Maryelle Vonlanthen, Stephen Fiedorek, Amy M. Scurlock, Stacie M. Jones, Robbie Pesek
Journal: Journal of Allergy and Clinical Immunology (2017)
First-in-human trial of 4'-thio-2'-deoxycytidine (TdCyd) in patients with advanced solid tumors
Authors: G. O'Sullivan Coyne, A. Chen, S. Kummar, J.M. Collins, R.S. Meehan, M. Suto, L. Rubinstein, R. Kinders, N. Moore, R. Parchment, Y. Horneffer, L. Juwara, M. Difilippantonio, R. Piekarz, J. Doroshow
Journal: Annals of Oncology (2016)
Impact of pretreatment C-reactive protein on overall survival for patients with metastatic renal cell carcinoma treated with sunitinib.
Authors: Yosuke Yasuda, Kazutaka Saito, Gen Sukegawa, Hajime Tanaka, Masaya Ito, Shinichi Kitsukawa, Takeshi Yuasa, Shinji Urakami, Shinya Yamamoto, Shunji Takahashi, Iwao Fukui, Junji Yonese
Journal: Journal of Clinical Oncology (2012)

436 Background: C-reactive protein (CRP) has been shown to be a significant prognostic factor for metastatic renal cell carcinoma (mRCC) in cytokine era. We further evaluated the prognostic impact of CRP for mRCC treated with sunitinib. Methods: Consecutive 37 patients were treated with sunitinib for mRCC from April 2008 to January 2011 at our institution. Seven patients were excluded because they received prior other tyrosine kinase inhibitors, sorafenib. Among eligible 30 patients, 9 patients (30%) had prior immunotherapy and 16 patients (55.5%) had prior nephrectomy. All clinical charts of the patients were reviewed for variables. Overall survival were estimated using the Kaplan-Meier method. Variables including hemoglobin, albumin, calcium, lactate dehydrogenase (LDH), thrombocytosis, number of the metastatic sites, ECOG performance status (PS), prior immunotherapy, prior nephrectomy, and pretreatment CRP concentration were evaluated. The cut-off point of pretreatment CRP concentration was set at 8mg/l. Multivariate analysis was carried out by Cox proportional hazard model. For all analysis the difference was considered significant when p &lt; 0.05. Results: Median follow up period was 9 months (range; 1 to 25 months). The 1-year overall and progression free survival rates for the entire cohort were 68.9% and 45.8%. During follow up, 6 patients (20 %) died of disease. In univariate analysis, pretreatment CRP was a significant factor for overall survival as well as thrombocytosis. Multivariate analysis showed pretreatment CRP was solely an independent prognostic factor for overall survival. The elevations of pretreatment CRP concentrations were found in 14 patients (46.7%). The median overall survival length of patients with nonelevated CRP concentrationswas not reached compared with that of patients with elevated CRP concentration of 9.9 months. The 1-year overall survival rates of the patients with preoperative CRP elevation (35.7%) were significantly worse than those of patients without CRP elevation (91.7%) (p = 0.012). Conclusions: CRP had also prognostic impact on overall survival for patients with mRCC treated with sunitinib.
Abstract B40: Lineage selective extracellular matrix interactions required for metastatic lung cancer
Authors: Don X. Nguyen
Journal: Cancer Research (2016)

Abstract Background: Lung cancers are biological heterogeneous malignancies with poor prognosis. The underlying mechanisms of this heterogeneity and their biological consequences for metastasis are poorly understood. We previously examined the molecular relationship between epithelial differentiation states, airway regeneration, lung cancer subtypes, and clinical outcome. By integrating genomics, bioinformatic, and experimental models of lung cancer metastasis, we identified a subset of metastatic lung adenocarcinoma (LUAD) defined by its expression of a novel cell lineage gene expression program (Cheung et al., Cancer Cell 2013). Results: Here we further define the molecular characteristics of this aggressive LUAD subgroup and find that it is driven by epigenetic silencing of know tumor suppressive non-coding RNAs, including mir-34a-c. This in turn activates genes encoding for specific extracellular matrix (ECM) interacting proteins. These ECM proteins include proteoglycans abundant in the inflammatory stroma of human lung cancers and lung tissue from patients with pulmonary fibrosis. Over-expressions of these proteoglycans and their corresponding cell surface receptors are defining features of recognized LUAD histotypes. In an experimental mouse model, genetic perturbations of these ECM/cell surface interactions inhibits the metastasis re-initiating capacity of LUAD cells to distant organs such as the brain. Significantly, these ECM-tumor cell interactions may also be disrupted using targeted agents currently in clinical trials. Conclusions: Our data provide a mechanistic link between the effectors of airway homeostasis, pulmonary fibrosis, and metastasis initiation by specific lung cancers. Consequently, we provide rational strategies to re-position current therapies to target the tumor microenvironment of metastatic lung adenocarcinomas. Citation Format: Don X. Nguyen. Lineage selective extracellular matrix interactions required for metastatic lung cancer. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Metastasis; 2015 Nov 30-Dec 3; Austin, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(7 Suppl):Abstract nr B40.
Absence of Inducible Costimulator (ICOS) on Alloreactive T Cells Reduces Graft-versus-Host-Disease While Leaving Graft-Versus-Tumor Activity Intact.
Authors: Vanessa M. Hubbard, Jeffrey M. Eng, Kartono H. Tjoe, Teresa Ramirez-Montagut, Stephanie J. Muriglan, Adam A. Kochman, Theis H. Terwey, Raffaella Schiro, Onder Alpdogan, Marcel R.M. van den Brink
Journal: Blood (2004)
A phase I/II safety and efficacy study of intratumoral light-activated drug therapy using talaporfin sodium in patients with inoperable hepatocellular carcinoma
Authors: S. Wang, L. Keltner, J. Winship, W. Lee
Journal: Journal of Clinical Oncology (2009)

e15684 Background: Light Infusion Therapy™ (Litx™) consists of the light-activated drug, talaporfin sodium (LS11®; mono-L-aspartyl chlorin e6), activated by a single-use, disposable device with an array of light-emitting diodes (LEDs). We evaluated talaporfin in combination with the light source in a phase 1/2 safety and efficacy trial in patients with hepatocellular carcinoma (HCC). To the best of our knowledge, this is the first clinical study of light-activated drug therapy in patients with HCC. Methods: Patients had confirmed primary HCC, 1–3 liver lesions, an ECOG score of 0–2, and a life expectancy of at least 16 weeks. Prior treatment failure with locally ablative techniques was allowed. The light-activated drug used in the study was talaporfin, a semi-synthesized, water-soluble chlorin e6 derivative. The LED device used in this study was a 1.5 mm diameter linear array of LEDs with a 25 mm emitting length at a wavelength of 664 nm. Patients underwent image-guided percutaneous placement of 1–4 LED device(s) using either local anesthesia or conscious sedation. The LED devices were used in single lesions or in multiple lesions. Following intratumoral placement of the LED devices, patients received talaporfin at 1 mg/kg IV bolus. Delivery of light energy commenced 15 min to 1 hr following drug administration with a total illumination time of 2.8 hrs. Results: The enrolled study group consisted of 8 patients. All 8 patients completed the week 4 assessment and were evaluated for tumor response. One (12.5%) out of 8 patients in this study was reported to have a complete response at week 4. Five patients (62.5%) were reported to have stable disease, and another 2 patients (25%) showed progressive disease. During the study, 7 patients reported a total of 16 treatment-related adverse events. There were no treatment-related adverse events that were greater than grade 2. At 1 year post treatment, all patients were alive. Conclusions: The results from this phase 2 study demonstrated that the therapy was safe for the treatment of HCC. A subsequent randomized controlled phase 3 pivotal trial is nearing completion and is designed to prove efficacy in patients with inoperable HCC. [Table: see text]
Phase 2 trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) for refractory germ-cell tumors (GCT).
Authors: Yago Nieto, Shi-Ming Tu, Roy B. Jones, Nizar M. Tannir, Roland L. Bassett, Kim Allyson Margolin, Leona Holmberg, Richard E. Champlin, Lance C. Pagliaro
Journal: Journal of Clinical Oncology (2014)

4517 Background: HDC is curative therapy for relapsed GCT. The Beyer model identifies groups with poor (5% EFS at 1-year post-HDC), intermediate (25% EFS), or good risk (≥50% EFS). Given high VEGF expression in metastatic GCT and BEV-chemotherapy synergy, we studied concurrent BEV/HDC and the efficacy of a novel regimen of infusional gemcitabine, docetaxel, melphalan, carboplatin (GDMC) (BBMT 2005;11:297) in refractory GCT. Methods: Eligibility: GCT in poor/interm-risk 1t relapse or in ≥2nd relapse. Patients (pts) received tandem HDC/ASCT with BEV (5 mg/kg) 1 week before each cycle. HDC#1: GDMC; HDC#2: ifosfamide/carboplatin/etoposide. Trial powered to distinguish an expected 1-yr EFS of 15% from a goal of 50%. Results: We treated 42 pts, median age 22 (19-45) (Table). HDC#1 main toxicities: mucositis (31 G3, 11 G2) and rash (3 G3, 12 G2). Among 7 pts with marginal renal function, there were 4 HDC-related deaths (3 sepsis, 1 fungal pneumonia). Protocol was amended to reduce HDC doses by 15% in 8 subsequent pts with high creatinine (1.5–1.8 mg/dl), with no more deaths. Tumor markers normalized in 83% pts. Surgery of residual lesions (N=9) showed necrosis (5), mature teratoma (1), necrosis+teratoma (2) and teratocarcinoma (1). Median follow-up from HDC#1 for alive pts is 22 (1-69) months. The 1- and 2-yr EFS rates are both 63% (95% CI, 49-81%). The 1- and 2-yr OS rates are 72% (59-89%) and 65% (50-84%), respectively. Conclusions: Tandem HDC with BEV/GDMC followed by BEV/ICE showed promising EFS in pts with heavily pretreated and refractory GCT, exceeding the expected results with carboplatin/etoposide and no BEV, and warrants testing in less heavily pretreated pts. Clinical trial information: NCI-2011-01631. N Beyer group Poor (23), interm (19) Origin Testic (35), mediast (4), retroperit (3) Cisplatin sensitivity Refractory (16), absolutely refractory (20) Prior surgery for metastases Retroperit (17), liver (1), other abdomen (5), lung (3), bone (1), brain (2), mediast (1) Prior xRT 9 Tumor markers at relapse /PD B-HCG (18), AFP (17), both (5) Median # prior regimens 4 (2-8) Histol Embryonal (6), chorio (6), yolk sac (4), teratoma (1), mixed (24) Metast Lungs (30), liver (12), bone (8), brain (6), retroperit (23), mediast (11) PD at HDC 22
A multicentre, international, randomised, open-label phase 3 trial of avelumab + best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100)
Authors: T. Powles, P. Grivas, J.B. Aragon-Ching, Y. Faroun, E.R. Kessler, Y. Tomita, D. Chakrabarti, R.J. Laliberte, M. Shnaidman, D. Petrylak
Journal: Annals of Oncology (2016)

Although first-line cisplatin-based chemotherapy prolongs survival in advanced urothelial cancer (UC), most patients (pts) progress within 8 months and no standard second-line therapies are currently available. Recent studies with anti-PD-L1 agents in pretreated UC have shown antitumour activity and promising survival compared with historical controls. Avelumab* (MSB0010718C) is a fully human anti-PD-L1 IgG1 antibody that has shown an acceptable safety profile and clinical activity across a range of tumour types in a large phase 1b study. In an expansion cohort of pts with pretreated UC, treatment with avelumab resulted in a 16% objective response and 59% disease control rate. A phase 3 study (NCT02603432) has been initiated to determine if maintenance therapy with avelumab can prolong the benefit of first-line chemotherapy in pts with advanced UC. Trial design: JAVELIN Bladder 100 is a phase 3, international, open-label trial of avelumab + best supportive care (BSC) compared with BSC alone administered as maintenance treatment for pts with locally advanced/metastatic UC whose disease did not progress after first-line treatment with 4–6 cycles of gemcitabine + cisplatin or gemcitabine + carboplatin. Other eligibility criteria include measurable disease prior to chemotherapy and adequate hematologic/organ function. Avelumab 10 mg/kg is administered every 2 wks as a 1 hr infusion. An estimated 668 pts will be randomized 1:1 and stratified based on best response to first-line chemotherapy and metastatic site. This trial has 2 co-primary populations: pts with PD-L1–positive tumours and all pts. The primary endpoint is overall survival and secondary endpoints include progression-free survival (PFS), objective response, safety, and symptoms/quality of life. Tumour response and PFS (RECIST v1.1) are assessed by blinded central review. Trial enrolment began in May 2016. *Proposed INN. Clinical trial identification: NCT02603432 Legal entity responsible for the study: N/A Pfizer Inc.
Early Reconstitution of Natural Killer Cells Following Non-Myeloablative Hematopoietic Stem Cell Transplantation Predicts the Development of Acute Graft-Versus-Host Disease.
Authors: Michael Boyiadzis, Frances T. Hakim, Sarfraz A. Memon, Robert Dean, Daniel Fowler, Ronald E. Gress, Michael R. Bishop
Journal: Blood (2006)
Two-step enhanced cancer immunotherapy with engineered <i>Salmonella typhimurium</i> secreting heterologous flagellin
Authors: Jin Hai Zheng, Vu H. Nguyen, Sheng-Nan Jiang, Seung-Hwan Park, Wenzhi Tan, Seol Hee Hong, Myung Geun Shin, Ik-Joo Chung, Yeongjin Hong, Hee-Seung Bom, Hyon E. Choy, Shee Eun Lee, Joon Haeng Rhee, Jung-Joon Min
Journal: Science Translational Medicine (2017)

Engineered Salmonella secreting heterologous bacterial flagellin suppress tumor growth by activating intratumoral macrophages.
Proinflammatory Cytokines Predict the Incidence and Progression of Distal Sensorimotor Polyneuropathy: KORA F4/FF4 Study
Authors: Christian Herder, Julia M. Kannenberg, Cornelia Huth, Maren Carstensen-Kirberg, Wolfgang Rathmann, Wolfgang Koenig, Margit Heier, Sonja Püttgen, Barbara Thorand, Annette Peters, Michael Roden, Christa Meisinger, Dan Ziegler
Journal: Diabetes Care (2017)

Experimental and epidemiological studies have implicated inflammatory processes in the pathogenesis of distal sensorimotor polyneuropathy (DSPN), but prospective studies are lacking. We hypothesized that biomarkers of inflammation predict the development and progression of DSPN in a population-based cohort.This study was based on participants aged 62-81 years from the Cooperative Health Research in the Region of Augsburg (KORA) F4/FF4 cohort, with a mean follow-up of 6.5 years. The predictive value of systemic levels of eight biomarkers of inflammation was assessed for incident DSPN in 133 incident case subjects and 397 individuals without incident DSPN, and for DSPN progression in 57 patients with prevalent DSPN at both time points.Higher hs-CRP, interleukin (IL)-6, tumor necrosis factor (TNF)-α, IL-1 receptor antagonist (IL-1RA), and soluble intercellular adhesion molecule (sICAM-1) and lower adiponectin levels were associated with incident DSPN in age- and sex-adjusted analysis; IL-18 and omentin were not. IL-6 (odds ratio 1.31 [95% CI 1.00-1.71]) and TNF-α (odds ratio 1.31 [95% CI 1.03-1.67]) remained associated with incident DSPN after adjusting for known DSPN risk factors. The addition of both cytokines to a clinical risk model improved model fit and reclassification. sICAM-1 and IL-1RA were positively associated with progression of DSPN.Systemic subclinical and vascular inflammation predicted both the onset and progression of DSPN over 6.5 years in an older general population. Thus modulation of inflammatory processes may be relevant to prevent and/or treat diabetic neuropathy.
Efficient Induction and Isolation of CMV-Specific CD8+ T Cells from CMV Seronegative Donors for the Treatment of CMV Reactivation in CMV Seropositive Patients Transplanted with a CMV Seronegative Donor.
Authors: Inge Jedema, Marian van de Meent, Pim L.J. van der Heiden, Erik W.A. Marijt, Pauline Meij, Roel Willemze, J.H. Frederik Falkenburg
Journal: Blood (2007)
Lenalidomide Is Effective in Heavily Pretreated Non Hodgkin Lymphoma (NHL): Analysis of a Retrospective Data Collection
Authors: Luigi Rigacci, Umberto Vitolo, M. Christina Cox, Liliana Devizzi, Alberto Fabbri, Alfonso Zaccaria, Francesco Zaja, Paolo Paesano, Giuseppe Rossi, Sergio Storti, Sante Tura, Pier Luigi Zinzani
Journal: Blood (2012)
Clinical Characterization, Prognostic Implications, and Response to Therapy In Patients with Myelodysplastic Syndrome (MDS) and Chromsome 17 Abnormality: A Single Institutional Experience
Authors: Tapan Kadia, Gautam Borthakur, Stefan Faderl, Farhad Ravandi, Jorge E. Cortes, Susan O'Brien, Elias Jabbour, Xiao Qin Dong, Sherry A. Pierce, Hagop M. Kantarjian, Guillermo Garcia-Manero
Journal: Blood (2010)
Drugs and drug-like molecules can modulate the function of mucosal-associated invariant T cells
Authors: Andrew N Keller, Sidonia B G Eckle, Weijun Xu, Ligong Liu, Victoria A Hughes, Jeffrey Y W Mak, Bronwyn S Meehan, Troi Pediongco, Richard W Birkinshaw, Zhenjun Chen, Huimeng Wang, Criselle D'Souza, Lars Kjer-Nielsen, Nicholas A Gherardin, Dale I Godfrey, Lyudmila Kostenko, Alexandra J Corbett, Anthony W Purcell, David P Fairlie, James McCluskey, Jamie Rossjohn
Journal: Nature Immunology (2017)
Comparison of PSA, FDG-PET, and Prostate Cancer Working Group 2 (PCWG2) criteria to interpret apparent progression on first post-treatment bone scan.
Authors: Karen A. Autio, Josef J. Fox, Eric Conrad Haupt, Heiko Schöder, Howard I. Scher, Steven M. Larson, Michael J. Morris
Journal: Journal of Clinical Oncology (2012)

20 Background: The risk of prematurely discontinuing effective therapy in patients with metastatic castrate resistant prostate cancer (mCRPC) because of apparent initial progression on bone scan has repercussions for drug development and clinical practice. We evaluated three methods to distinguish disease progression (POD) from non-progressive bone disease or flare response. Methods: The dataset was comprised of men with mCRPC enrolled in contemporary clinical trials using AR-directed or targeted therapy. To be included, a worsened bone scan (increased size, intensity, or number of lesions) at the time of initial follow-up at 8-12 wks (FU1), a concurrently performed FDG-PET and PSA, and a second follow-up bone scan (FU2) &gt; 6 wks after FU1 were required. Pts were evaluated by three methods: 1) PSA-guided approach: POD was defined as a PSA increase &gt;25% from baseline at FU1; for non-progressors, a special category was created for flare response defined as a PSA decline &gt;50% and a FU2 bone scan documenting stability/improvement; 2) FDG-PET approach: POD was defined as a new bone lesion or increase in SUV &gt;10% at FU1; 3) Bone scan only approach: POD was defined by PCWG2 requiring 2 new bone scan lesions at FU1 and 2 additional lesions at FU2. Results: 66 pts registered to trials conducted between 2007-2011 were examined; 38/66 (57.6%) pts had a worsened bone scan at FU1, 23 of whom had a FU2 bone scan and were considered evaluable for this analysis. Conclusions: Over half of mCRPC pts have a worsening bone scan during the first three months of therapy. PCWG2 controls for flare without use of PSA, confirms radiographic POD, and maintains pts on study longer than use of early post-treatment PSA changes. FDG-PET at first assessment appears to identify an identical percentage of progressors as PCWG2 did at the second assessment. PCWG2 is undergoing prospective validation in phase III trials; the use of FDG PET as an early response biomarker is currently under investigation. [Table: see text]
Phase II Optimization, Open-Label Clinical Trial of Zalypsis® (PM00104) in Relapsed/Refractory Multiple Myeloma Patients
Authors: Enrique M Ocio, Javier De La Rubia, Albert Oriol-Rocafiguera, Joan Blade, Jose Rodriguez, Cinthya Coronado, Jesus Martin Sanchez, Ana Isabel Teruel, Dolores Hernandez-Maraver, Felipe Prosper, Jesus. F San-Miguel
Journal: Blood (2012)
Biweekly cabazitaxel as post-docetaxel treatment for metastatic castration resistant prostate cancer (mCRPC): Findings from an early safety analysis of the Prosty II trial.
Authors: Pirkko-Liisa Irmeli Kellokumpu-Lehtinen, Timo Marttila, Petteri Hervonen, Vesa V Kataja, Tapio Utriainen, Marjaana Luukkaa, Mikko Taalikka, Anna-Liisa Kautio
Journal: Journal of Clinical Oncology (2015)

276 Background: Docetaxel (D) administered at 2-week intervals was better tolerated than the standard 3-week D in mCRPC. In addition, the overall survival was better with the 2-weekly D dosing in our Prosty I trial (Kellokumpu-Lehtinen et al. Lancet Oncol 2013;14:117-124). The aim of the Prosty II trial was to evaluate the safety of 2-weekly cabazitaxel (C) as post-docetaxel treatment for m CRPC. The safety of the first 40 patient (pts) is reported below. Methods: 40 pts were allocated to receive C 16 mg/m² i.v. d1 and d14 q4 wks. At baseline, WHO performance status was 0 in 33% of pts and 1 in 67% of pts and the median serum PSA level was 342 µg/L (range 3.7-2425)). The primary endpoint was safety. Study identifier: NCT01558219. Results: A total number of 144 cycles of C were administered. No prophylactic G-CSF was used. The most common Grade 3/4 adverse events (AE, expressed as % pts experienced Grade3 or Grade 4 AE) were neutropenia 12.5/2.5%, pain 12.5/0%, fatique 5/2.5%, anemia 5.0/0%, neutropenic infections 2.5/0%, leucopenia 2.5/0%, mucositis 2.5/0%, increase of alkaline phosphatase 5/0% and limb edema 2.5/0. In addition one Grade 4 pulmonary embolism and one intracerebral hemorrhage occurred. In one pt, cancer related bone fracture occurred during the second C cycle (Grade 4 AE). Altogether up to cycle 6 no AE was reported in 1 pt (2.5%), Grade 1 AE in 3 pts (7.5%), Grade 2 in 17 pts (42.5%), Grade 3 in 13 pts (32.5%) and Grade 4 in 5 pts (12.5%). Conclusions: Biweekly cabazitaxel seems to be well tolerated treatment for heavily pretreated advanced mCRPC patients.